Accès ouvert
2024
conference-abstract
OpenAlex
Martyna C. Popis, Efrat Altman Sharoni, Shanmugarajan Krishnan, Deborah Wright et autres
Background Targeted cancer therapy aims to eradicate cancer cells while preserving healthy tissue, significantly improving the therapeutic index compared to conventional treatments. Antibodies are crucial in these targeted therapies due to their exceptional specificity for target antigens. Advancements in T-cell biology have …
us
(code pays fourni par la source)
Accès ouvert
2022
conference-abstract
OpenAlex
Eleni Chantzoura, Efrat Altman Sharoni, Reed Masakayan, Martyna C. Popis et autres
Background We are developing MiNK-413; a novel allogeneic CAR-iNKT product targeting BCMA and secreting soluble IL-15 for treatment of relapsed/refractory Multiple Myeloma (rrMM). Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized treatment of rrMM with two autologous products already approved by the …
Accès ouvert
2022
conference-abstract
OpenAlex
Xavier Michelet, Martyna C. Popis, Shannon Kathryn Boi, Magdalena Niedzielska et autres
Background The emergence of antibodies targeting checkpoint modulators such as PD-1 and CTLA-4 has revolutionized solid tumor treatment and highlighted the importance of effectively engaging the immune system to drive durable responses. However, well over 50% of solid tumor patients do not …
us
(code pays fourni par la source)